Dr Reddy’s Lab is currently trading at Rs. 1797.90, up by 3.60 points or 0.20% from its previous closing of Rs. 1794.30 on the BSE.
The scrip opened at Rs. 1789.50 and has touched a high and low of Rs. 1804.00 and Rs. 1781.70 respectively. So far 7,629 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1968.60 on 25-Jan-2013 and a 52 week low of Rs. 1528.00 on 19-Jun-2012.
Last one week high and low of the scrip stood at Rs. 1845.35 and Rs. 1783.35 respectively. The current market cap of the company is Rs. 30,521 crore.
The promoters holding in the company stood at 25.56% while Institutions and Non-Institutions held 40.15% and 17.63% respectively.
Dr Reddy’s Laboratories has called back its anti-depression drug Citalopram from the US market, as it has received complaints of a strong odor. It makes 50% its revenues from the US business, where it sells a variety of products, including Para IV filings targeting patented drugs and various low-competition products. The drug maker has recalled this drug with the knowledge of the US Food and Drug Administration (USFDA) and there will be no material financial impact from it.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1872.60 |
| Dr. Reddys Labs. | 1376.30 |
| Cipla | 1453.50 |
| Zydus Lifesciences | 1121.65 |
| Lupin | 2407.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: